Abstract:The HIV-1 CA protein has gained remarkable attention as a promising therapeutic target for the development of new antivirals, due to its pivotal roles in HIV-1 replication (structural and regulatory). Herein, we report the design and synthesis of three series of benzenesulfonamide-containing phenylalanine derivatives obtained by further structural modifications of PF-74 to aid in the discovery of more potent and drug-like HIV-1 CA inhibitors. Structure-activity relationship studies of these compounds led to the identification of new phenylalanine derivatives with a piperazinone moiety, represented by compound 11l, which exhibited anti-HIV-1(NL4-3) activity 5.78-fold better than PF-74. Interestingly, 11l also showed anti-HIV-2(ROD) activity (EC50 = 31 nM), with almost 120 times increased potency over PF-74. However, due to the higher significance of HIV-1 as compared to HIV-2 for the human population, this manuscript focuses on the mechanism of action of our compounds in the context of HIV-1. SPR studies on representative compounds confirmed CA as the binding target. The action stage determination assay demonstrated that these inhibitors exhibited antiviral activities with a dual-stage inhibition profile. The early-stage inhibitory activity of compound 11l was 6.25 times more potent as compared to PF-74 but appeared to work via the accelerating capsid core assembly rather than stabilization. However, the mechanism by which they exert their antiviral activity in the late stage appears to be the same as PF-74 with less infectious HIV-1 virions produced in their presence, as judged p24 content studies. MD simulations provided the key rationale for the promising antiviral potency of 11l. Additionally, 11l exhibited a modest increase in HLM and human plasma metabolic stabilities as compared to PF-74, as well as a moderately improved pharmacokinetic profile, favorable oral bioavailability, and no acute toxicity. These studies provide insights and serve as a starting point for subsequent medicinal chemistry efforts in optimizing these promising HIV inhibitors.

Design, synthesis and anti-HIV-1 evaluation of hydrazide-based peptidomimetics as selective gelatinase inhibitors.

Design, Synthesis and Preliminary Evaluation of New Cinnamoyl Pyrrolidine Derivatives As Potent Gelatinase Inhibitors

Design, Synthesis and Activity Evaluation of Novel Peptide Fusion Inhibitors Targeting HIV-1 Gp41

Design, Synthesis, and Biological Evaluation of Novel 2‐(pyridin‐3‐yloxy)acetamide Derivatives As Potential Anti‐HIV‐1 Agents

Design, Synthesis and Biological Evaluation of Novel Galloyl Derivatives as HIV-1 RNase H Inhibitors.

Design, Synthesis, and Biological Evaluation of Novel Double-Winged Galloyl Derivatives As HIV-1 RNase H Inhibitors.

Design, Synthesis, and Biological Evaluation of Highly Potent Small Molecule–Peptide Conjugates As New HIV-1 Fusion Inhibitors

Design, Synthesis, and Biological Evaluation of Novel Benzoyl Diarylamine/ether Derivatives as Potential Anti-HIV-1 Agents.

Small molecule fusion inhibitors: design, synthesis and biological evaluation of (Z)-3-(5-(3-benzyl-4-oxo-2-thioxothiazolidinylidene)methyl)-N-(3-carboxy-4-hydroxy)phenyl-2,5-dimethylpyrroles and related derivatives targeting HIV-1 gp41.

Design of the artificial N-peptides with coiled-coil trimer structure against HIV-1 based on the SWISS MODEL and HDOCK-aided strategy

Synthesis and Gelatinase (MMP-2, MMP-9) Inhibitory Activities of Pyrrolidine Derivatives

Design, Synthesis, and Mechanism Study of Dimerized Phenylalanine Derivatives As Novel HIV-1 Capsid Inhibitors.

Design and Biological Evaluation of M-Xylene Thioether-Stapled Short Helical Peptides Targeting the HIV-1 Gp41 Hexameric Coiled-Coil Fusion Complex.

Design, Synthesis and Biological Evaluation of 3-Substituted 2,5-Dimethyl-n-(3-(1h-tetrazol-5-yl)phenyl)pyrroles As Novel Potential HIV-1 Gp41 Inhibitors

Design, Synthesis, and Antiviral Evaluation of Novel Hydrazone‐substituted Thiophene[3,2‐d]pyrimidine Derivatives As Potent Human Immunodeficiency Virus‐1 Inhibitors

Design, Synthesis and Biological Evaluation of Thiazolo[3, 2-A]pyrimidine Derivatives As Novel RNase H Inhibitors

Design, synthesis and biological evaluation of protease inhibitors containing morpholine cores with remarkable potency against both HIV-1 subtypes B and C

Discovery of Novel 1,4-Disubstituted 1,2,3-Triazole Phenylalanine Derivatives As HIV-1 Capsid Inhibitors

Synthesis and Biological Evaluation of a Series of 2-(((5-akly/aryl-1h-pyrazol-3-yl)methyl)thio)-5-alkyl-6-(cyclohexylmethyl)-pyrimidin-4(3h)-ones As Potential HIV-1 Inhibitors.

Sulphonamide 1,4-dithia-7-azaspiro[4,4]nonane derivatives as gelatinase A inhibitors.

Rational Design of Sulfonyl-?-AApeptides as Highly Potent HIV-1 Fusion Inhibitors with Broad-Spectrum Activity